Возраст домена | n/a |
Дата окончания | n/a |
ИКС | n/a |
Страниц в Google | 180 |
Страниц в Яндексе | 52 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 1573651 |
Alexa Country | ![]() |
История изменения показателей | Авторизация |
Aduro Biotech | Discovering and Developing Immunotherapies.
n/a
Aduro is a clinical-stage cancer immunotherapy company with multiple therapeutic approaches in development that have the potential to yield powerful immunotherapy combinations.
UTF-8
15 КБ
302
2 511 симв.
2 178 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
![]() ![]() |
15 | 7 |
240 | 8338 | ![]() | |
![]() ![]() |
9 | 9 |
0 | 5 | ![]() | |
![]() ![]() |
9 | 8 |
0 | 113 | ![]() | |
![]() ![]() |
6 | 8 |
375 | 10949 | ![]() | |
![]() ![]() |
6 | 8 |
0 | 9304 | ![]() | |
![]() ![]() |
5 | 8 |
0 | 289 | ![]() | |
![]() ![]() |
5 | 6 |
0 | 29797 | ![]() | |
![]() ![]() |
4 | 9 |
0 | 25 | ![]() | |
![]() ![]() |
4 | 6 |
0 | 87045 | ![]() | |
![]() ![]() |
4 | 8 |
1000 | 4981 | ![]() | |
Еще 40 сайтов после авторизации |
Данные предоставлены сервисом semrush
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
![]() | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 23 Февраля 2015 ) | |
Количество ссылок на сайт | 27 |
Количество доменов, которые ссылаются на сайт | 14 |
Количество найденных анкоров | 12 |
Исходящие (внешние) ссылки домена | 84 |
Количество доменов, на которые ссылается сайт | 24 |
Количество исходящих анкоров | 25 |
Внешние ссылки главной страницы ( 3 ) | |
hanechow.com | Hane Chow, Inc. |
twitter.com/ | |
linkedin.com/ | |
Внутренние ссылки главной страницы ( 37 ) | |
/ | <img> |
/technology/immunotherapy/ | Immunotherapy |
/technology/sting/ | STING Pathway |
/technology/b-select/ | APRIL Pathway |
/pipeline/clinical-trials/ | Clinical Trials |
investors.aduro.com/sec-filings/sec-filing/10-k/0001564590-1... | View Online |
investors.aduro.com/news-releases/news-release-details/aduro... | Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Com... |
investors.aduro.com/news-releases/news-release-details/aduro... | Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results |
investors.aduro.com/news-releases/news-release-details/aduro... | Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (... |
investors.aduro.com/news-releases | Press Releases |
/careers/ | Careers |
/about/ | About Aduro |
/about/leadership/ | Leadership |
/about/board-of-directors/ | Board of Directors |
/about/scientific-advisory-board/ | Scientific Advisory Board |
/about/global-headquarters/ | Global Headquarters |
/about/community-affairs/ | Community Affairs |
/pipeline/ | Pipeline |
/pipeline/access-to-our-investigational-agents/ | Access to Our Investigational Agents |
/technology/ | Technology |
/technology/scientific-publications/ | Scientific Publications |
/technology/intellectual-property/ | Intellectual Property |
/partnerships/ | Partnerships |
/media/ | Media |
investors.aduro.com | Investors |
investors.aduro.com/events-and-presentations/upcoming-events | Events & Presentations |
investors.aduro.com/corporate-governance/highlights | Corporate Governance |
investors.aduro.com/corporate-governance/committee-compositi... | Committee Composition |
investors.aduro.com/financial-information/sec-filings | Financials & Filings |
investors.aduro.com/financial-information/annual-reports | Annual Reports |
investors.aduro.com/analyst-coverage | Analyst Coverage |
investors.aduro.com/stock-information/stock-quote | Stock Information |
investors.aduro.com/stock-information/stock-chart | Stock Chart |
investors.aduro.com/investor-faqs | FAQs |
/contact/ | Contact |
/privacy-policy/ | Privacy Policy |
/terms-of-use/ | Terms and Conditions of Use |
User-agent: *
Crawl-delay: 10
США - 63.80.4.10
WS/Akamai Technologies/Akamai Technologies
Verizon Business
HTTP/1.1 200 OK
Date: Wed, 04 Dec 2019 19:21:14 GMT
Server: Apache
X-Frame-Options: SAMEORIGIN
Vary: User-Agent,Accept-Encoding
ETag: 2xjg8w
Cache-Control: max-age=30, s-maxage=30
Expires: Wed, 04 Dec 2019 19:21:44 GMT
X-hccms: hit
Content-Length: 15363
Content-Type: text/html;charset=UTF-8
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"